• A Very Meh-Ry Biotech Year and What’s Ahead in 2025

  • Dec 25 2024
  • Length: 40 mins
  • Podcast

A Very Meh-Ry Biotech Year and What’s Ahead in 2025

  • Summary

  • We continue our holiday tradition by welcoming STAT News Senior Biotech Writer Adam Feuerstein for our annual look back at the year that was in biotech and what’s ahead for the industry with the JPMorgan healthcare conference and beyond in 2025. Feuerstein offers his view on finance and dealmaking in 2024, new drug approvals, and his annual take on the best and worst CEOs of the year. We also discuss what Trump 2.0 may look like for the industry, changes coming to the FDA and other agencies, and what hot technologies to watch in the year ahead.

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about A Very Meh-Ry Biotech Year and What’s Ahead in 2025

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.